DTIL, US74019P2074

Precision BioSciences stock fell 3.25 percent during biotech event

Published on 10/07/2026 at 07:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Precision BioSciences stock fell 3.25 percent to USD 6.11 on October 6, 2026. Q2 cash of USD 112 million funds clinical programs through 2028.

DTIL, US74019P2074, Illustration mit AI erstellt.

Precision BioSciences (ISIN US74019P2074) was trading at USD 6.11 on Nasdaq on October 6, 2026, down 3.25 percent from the previous close of USD 6.31. The move came as the company appeared on the schedule for biotechnology presentations at Meeting on the Mesa.

Gene editing takes center stage

According to Stocktwits on October 5, 2026, Precision BioSciences was among the companies scheduled for spotlight presentations during the Meeting on the Mesa program. The event gives the clinical-stage biotechnology company a timely setting to present its pipeline while the stock remains 36.49 percent below its 52-week high of USD 9.62.

Precision is advancing PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. The programs use the company's ARCUS genome-editing platform in different therapeutic settings, making clinical data the central valuation driver rather than current product revenue.

Cash supports the pipeline

In a transcript of the H.C. Wainwright conference, Investing.com reported on September 17, 2026, that Precision ended the second quarter of 2026 with USD 112 million in cash and cash equivalents. Management said that balance provides a runway through 2028, giving the company time to advance both clinical programs.

The funding position must be weighed against quarterly profitability. Markets Insider reported on September 22, 2026, that the quarter ending June 30 produced a GAAP net loss of USD 32.65 million. The same report said H.C. Wainwright maintained a Buy rating and a USD 60.00 price target.

Clinical milestones set the test

The H.C. Wainwright discussion described PBGENE-HBV as a Phase I program targeting cccDNA, the viral reservoir associated with chronic hepatitis B. Precision said 16 patients had received 38 administrations and that all patients with detectable baseline pgRNA reached durable undetectable levels.

PBGENE-DMD began dosing in August 2026, with initial safety data targeted for the end of 2026 and biopsy data expected in 2027. Both milestones matter because the programs remain in early clinical testing, so safety, biomarker response and durability will determine whether the platform can convert scientific progress into a broader development case.

DTIL stock remains below yearly high

Precision BioSciences stock was last at USD 6.11 on Nasdaq at 2:03 p.m. EDT on October 6, 2026. Its market capitalization was USD 174.2 million, and the session range was USD 6.11 to USD 6.40, keeping the shares 36.49 percent below the 52-week high.